Transcriptional Controls in Leukaemia Team
Team Leader: Dr Arthur Zelent
Location: Brookes-Lawley Building, Sutton
Section: Section of Haemato-Oncology
Collectively, haematological malignancies account for approximately 8% of all cancers with a considerably higher (>3 fold) proportion of childhood cancers (ref1). In the UK, 600 children and 24,000 adults are diagnosed with a haematological cancer each year. During the past 20 years the overall incidence of haematological cancers in the Western world has increased, primarily due to the increase in NHL and AML in adults (ref2). Despite remarkable advances in the treatment of haematological cancers that have been achieved over the past few decades, treatment failure, relapse and mortality rates, particularly in adults and specific subtypes of paediatric leukaemias (those with MLL rearrangements, for example), remain unacceptably high. It is reasonable to predict that cure rates will not improve significantly unless alternative treatment modalities to conventional radiotherapy/chemotherapy are developed.
The goal of our research is focused on the development of better approaches to cancer treatment through elucidation of molecular mechanisms underlying transcriptional deregulation and pathogenesis of leukaemia.
In the Section of Haemato-Oncology
